{
    "clinical_study": {
        "@rank": "78789", 
        "arm_group": [
            {
                "arm_group_label": "VX-135 High Dose with ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of a high dose of VX-135 in combination with ribavirin"
            }, 
            {
                "arm_group_label": "VX-135 Low Dose with ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of a low dose of VX-135 in combination with ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135\n      in combination with ribavirin in treatment-na\u00efve subjects with chronic hepatitis C"
        }, 
        "brief_title": "A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C", 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Subjects  (male and female) must be between the ages of 18 and 60 years at screening\n\n          -  Subjects must have genotype 1 Chronic Hepatitis C\n\n          -  Subjects must be treatment na\u00efve\n\n          -  Subjects must have laboratory values at screening within limits as specified by the\n             protocol\n\n        Key Exclusion Criteria:\n\n          -  Evidence of cirrhosis\n\n          -  Female subjects who are pregnant or nursing or male subjects with a female partner of\n             childbearing potential who is unwilling to adhere to the contraception requirements,\n             is pregnant or nursing, or planning to become pregnant during the study\n\n          -  Any other cause of significant liver disease in addition to hepatitis C\n\n          -  Human immunodeficiency virus -1 or -2\n\n          -  Diagnosis of or suspected hepatocellular carcinoma\n\n          -  History of organ transplant, with the exception of corneal transplants and skin\n             grafts"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726946", 
            "org_study_id": "VX12-135-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VX-135 High Dose with ribavirin", 
                    "VX-135 Low Dose with ribavirin"
                ], 
                "description": "12 weeks of VX-135", 
                "intervention_name": "VX-135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "VX-135 High Dose with ribavirin", 
                    "VX-135 Low Dose with ribavirin"
                ], 
                "description": "12 weeks of ribavirin", 
                "intervention_name": "ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Hepatitis C", 
            "HCV", 
            "CHC"
        ], 
        "lastchanged_date": "June 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marietta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Georgia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Germantown", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Tennessee"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Texas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Texas"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C", 
        "overall_official": {
            "affiliation": "Vertex Pharmaceuticals Incorporated", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms, echocardiograms (Cohorts 1 and 2 only),  and laboratory assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects who have an SVR at 4 weeks after the last planned dose of treatment (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have an SVR at 24 weeks after the last planned dose of treatment (SVR24)", 
                "safety_issue": "No", 
                "time_frame": "36 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have virologic relapse", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Viral kinetics, as determined at different time points by the proportion of subjects who achieve:  -Undetectable HCV RNA -<LLOQ HCV RNA", 
                "safety_issue": "No", 
                "time_frame": "Up to 64 weeks"
            }, 
            {
                "description": "as measured by on-treatment HCV RNA values", 
                "measure": "The proportion of subjects who have virologic breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)", 
                "safety_issue": "No", 
                "time_frame": "up to 28 weeks"
            }, 
            {
                "measure": "The amino acid sequence of the nonstructural (NS)5B protein in subjects who fail treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to 60 weeks"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}